{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T23:07:08Z","timestamp":1765667228002,"version":"3.37.3"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"NIHR Manchester Biomedical Research Centre","doi-asserted-by":"publisher","award":["IS-BRC-1215-20007"],"award-info":[{"award-number":["IS-BRC-1215-20007"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.ejca.2018.09.019","type":"journal-article","created":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T21:43:55Z","timestamp":1542836635000},"page":"45-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["European Breast Cancer Council manifesto 2018: Genetic\u00a0risk prediction testing in breast cancer"],"prefix":"10.1016","volume":"106","author":[{"given":"Emiel","family":"Rutgers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Balmana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Beishon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3893-1049","authenticated-orcid":false,"given":"Karen","family":"Benn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8482-5784","authenticated-orcid":false,"given":"D. Gareth","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Mansel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8494-732X","authenticated-orcid":false,"given":"Paul","family":"Pharoah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Perry Skinner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Stoppa-Lyonnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luzia","family":"Travado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynda","family":"Wyld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2013","series-title":"My medical choice","author":"Jolie","key":"10.1016\/j.ejca.2018.09.019_bib1"},{"issue":"6","key":"10.1016\/j.ejca.2018.09.019_bib2","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s10897-016-9973-6","article-title":"The impact of Angelina Jolie (AJ)\u2019s story on genetic referral and testing at an academic cancer centre in Canada","volume":"25","author":"Raphael","year":"2016","journal-title":"J Genet Counsel"},{"issue":"5","key":"10.1016\/j.ejca.2018.09.019_bib3","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1186\/s13058-014-0442-6","article-title":"The Angelina Jolie effect: how high celebrity profile can have major impact on provision of cancer related services","volume":"16","author":"Evans","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2018.09.019_bib4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s10897-016-9982-5","article-title":"A retrospective exploration of the impact of the \u2018Angelina Jolie effect\u2019 on the single state-wide familial cancer program in Perth, Western Australia","volume":"26","author":"Freedman","year":"2017","journal-title":"J Genet Counsel"},{"key":"10.1016\/j.ejca.2018.09.019_bib5","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ejca.2016.10.023","article-title":"European breast cancer conference manifesto on breast centres\/units","volume":"72","author":"Cardoso","year":"2017","journal-title":"Eur J Cancer"},{"issue":"34","key":"10.1016\/j.ejca.2018.09.019_bib6","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1200\/JCO.2016.67.0554","article-title":"Population frequency of germline BRCA1\/2 mutations","volume":"34","author":"Maxwell","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.09.019_bib7","unstructured":"National Cancer Institute. BRCA mutations: cancer risk and genetic testing. https:\/\/www.cancer.gov\/about-cancer\/causes-prevention\/genetics\/brca-fact-sheet."},{"key":"10.1016\/j.ejca.2018.09.019_bib8","article-title":"Approaches to understanding breast cancer","volume":"151","author":"Winters","year":"2017"},{"issue":"23","key":"10.1016\/j.ejca.2018.09.019_bib9","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2018.09.019_bib10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41523-017-0024-8","article-title":"The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk","volume":"3","author":"Slavin","year":"2017","journal-title":"NPJ Breast Cancer"},{"year":"2017","series-title":"Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer","author":"National Institute for Health and Care Excellence (NICE)","key":"10.1016\/j.ejca.2018.09.019_bib11"},{"key":"10.1016\/j.ejca.2018.09.019_bib12","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.15585\/mmwr.mm6546a3","article-title":"CDC grand rounds: family history and genomics as tools for cancer prevention and control","volume":"65","author":"Rodriguez","year":"2016","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ejca.2018.09.019_bib13","unstructured":"NHS England. Clinical commissioning policy: genetic testing for BRCA1 and BRCA2 mutations. E01\/P\/b. https:\/\/www.england.nhs.uk\/commissioning\/wp-content\/uploads\/sites\/12\/2015\/10\/e01pb-brca-ovarian-cancer-oct15.pdf."},{"key":"10.1016\/j.ejca.2018.09.019_bib14","unstructured":"Peshkins BN, Isaacs C. Prevalence of BRCA1 and BRCA2 mutations and associated cancer risks. UpToDate 2018. https:\/\/www.uptodate.com\/contents\/prevalence-of-brca1-and-brca2-mutations-and-associated-cancer-risks."},{"issue":"3","key":"10.1016\/j.ejca.2018.09.019_bib15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s13167-010-0037-y","article-title":"Founder BRCA1\/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control","volume":"1","author":"Janavi\u010dius","year":"2010","journal-title":"EPMA J"},{"key":"10.1016\/j.ejca.2018.09.019_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cancergen.2017.10.002","article-title":"Comprehensive BRCA mutation analysis in the Greek population. Experience from a single clinical diagnostic center","volume":"220","author":"Apessos","year":"2018","journal-title":"Cancer Genet"},{"issue":"10","key":"10.1016\/j.ejca.2018.09.019_bib17","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1038\/ejhg.2016.63","article-title":"Guidelines for diagnostic next-generation sequencing","volume":"24","author":"Matthijs","year":"2016","journal-title":"Eur J Hum Genet"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2018.09.019_bib18","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/ejhg.2016.94","article-title":"New challenges for BRCA testing: a view from the diagnostic laboratory","volume":"24","author":"Wallace","year":"2016","journal-title":"Eur J Hum Genet"},{"issue":"5","key":"10.1016\/j.ejca.2018.09.019_bib19","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/bjc.2017.223","article-title":"A comparative study of germline BRCA1 and BRCA2 mutation screening methods in use in 20 European clinical diagnostic laboratories","volume":"117","author":"Ellison","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2018.09.019_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx265","article-title":"Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation testing in unselected general population women","author":"Manchanda","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2018.09.019_bib21","doi-asserted-by":"crossref","first-page":"k180","DOI":"10.1136\/bmj.k180","article-title":"Young women with BRCA mutation can safely postpone radical surgery","volume":"360","author":"Wise","year":"2018","journal-title":"BMJ"},{"year":"2013","series-title":"Warning letter","author":"US Food and Drug Administration","key":"10.1016\/j.ejca.2018.09.019_bib22"},{"issue":"3","key":"10.1016\/j.ejca.2018.09.019_bib23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10897-011-9475-5","article-title":"Psychological distress with direct-to-consumer genetic testing: a case report of an unexpected BRCA positive test result","volume":"21","author":"Dohany","year":"2012","journal-title":"J Genet Counsel"},{"issue":"13","key":"10.1016\/j.ejca.2018.09.019_bib24","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1200\/JCO.2015.63.7454","article-title":"Panel testing for familial breast cancer: calibrating the tension between research and clinical care","volume":"34","author":"Thompson","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2018.09.019_bib25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/jmedgenet-2016-104125","article-title":"The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study","volume":"54","author":"Evans","year":"2017","journal-title":"J Med Genet"},{"key":"10.1016\/j.ejca.2018.09.019_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/gim.2018.38","article-title":"False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care","author":"Tandy-Connor","year":"2018","journal-title":"Genet Med"},{"year":"2017","series-title":"DNA test kits: consider the privacy implications","author":"Federal Trade Commission","key":"10.1016\/j.ejca.2018.09.019_bib27"},{"year":"2017","series-title":"\u2018Damaged for the rest of my life\u2019: Woman says surgeons mistakenly removed her breasts and uterus","author":"Bever","key":"10.1016\/j.ejca.2018.09.019_bib28"},{"issue":"10","key":"10.1016\/j.ejca.2018.09.019_bib29","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1245\/s10434-017-5959-3","article-title":"Clinical decision-making in patients with variant of uncertain significance in BRCA1 or BRCA2 genes","volume":"24","author":"Welsh","year":"2017","journal-title":"Ann Surg Oncol"},{"year":"2013","series-title":"A beginner's guide to BRCA1 and BRCA2","author":"Royal Marsden NHS Foundation Trust","key":"10.1016\/j.ejca.2018.09.019_bib30"},{"issue":"3","key":"10.1016\/j.ejca.2018.09.019_bib31","article-title":"Direct-to-consumer genetic testing: where and how does genetic counseling fit?","volume":"14","author":"Middleton","year":"2017","journal-title":"Personalised Med"},{"issue":"17","key":"10.1016\/j.ejca.2018.09.019_bib32","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1016\/j.ejca.2013.07.017","volume":"49","author":"Wilson","year":"2013","journal-title":"Eur J Cancer"},{"year":"2016","series-title":"European quality assurance scheme for breast cancer services: scope","author":"European Commission","key":"10.1016\/j.ejca.2018.09.019_bib33"},{"issue":"1","key":"10.1016\/j.ejca.2018.09.019_bib34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/IGC.0000000000001122","article-title":"Breadth of genetic testing selected by patients at risk of hereditary breast and ovarian cancer","volume":"28","author":"Szender","year":"2018","journal-title":"Int J Gynecol Canc"},{"issue":"10","key":"10.1016\/j.ejca.2018.09.019_bib35","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.annepidem.2017.09.005","article-title":"BRCA2 genes: how poor is the prognosis?","volume":"27","author":"Faulty BRCA1","year":"2017","journal-title":"Ann Epidemiol"},{"issue":"3","key":"10.1016\/j.ejca.2018.09.019_bib36","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10689-017-9970-4","article-title":"Supporting disclosure of genetic information to family members: professional practice and timelines in cancer genetics","volume":"16","author":"Derbez","year":"2017","journal-title":"Fam Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2018.09.019_bib37","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.2196\/resprot.8138","article-title":"Cancer predisposition cascade screening for hereditary breast\/ovarian cancer and lynch syndromes in Switzerland: study protocol","volume":"6","author":"Katapodi","year":"2017","journal-title":"JMIR Res Protoc"},{"key":"10.1016\/j.ejca.2018.09.019_bib38","article-title":"Evaluation of breast cancer patients with genetic risk in a university hospital: before and after the implementation of a heredofamilial cancer unit","author":"Lobo","year":"2017","journal-title":"J Genet Counsel"},{"key":"10.1016\/j.ejca.2018.09.019_bib39","doi-asserted-by":"crossref","DOI":"10.1177\/1557988317753241","article-title":"\u2018Guys don't have breasts\u2019: the lived experience of men who have BRCA gene mutations and are at risk for male breast cancer","author":"Skop","year":"2018","journal-title":"Am J Men's Health"},{"key":"10.1016\/j.ejca.2018.09.019_bib40","unstructured":"Regulation (EU) 2017\/746 of the European Parliament and of the Council of 5 April 2017 on in\u00a0vitro diagnostic medical devices and repealing Directive 98\/79\/EC and Commission Decision 2010\/227\/EU. http:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX%3A32017R0746."},{"year":"2017","series-title":"The EU's In\u00a0Vitro Diagnostics (IVD) regulation: a summary of the regulatory requirements for software and genetic tests","author":"GeneWatch UK","key":"10.1016\/j.ejca.2018.09.019_bib41"},{"key":"10.1016\/j.ejca.2018.09.019_bib42","first-page":"1","article-title":"Legislation of direct-to-consumer genetic testing in Europe: a fragmented regulatory landscape","author":"Kalokairinou","year":"2017","journal-title":"J Community Genet"},{"year":"2008","series-title":"Additional protocol to the convention on human rights and biomedicine, concerning genetic testing for health purposes","author":"Council of Europe","key":"10.1016\/j.ejca.2018.09.019_bib43"},{"key":"10.1016\/j.ejca.2018.09.019_bib44","doi-asserted-by":"crossref","unstructured":"European Society of Human Genetics. Statement of the ESHG on direct-to-consumer genetic testing for health-related purposes. Eur J Hum Genet 18(12):1271\u20131273. https:\/\/doi.org\/10.1038\/ejhg.2010.129.","DOI":"10.1038\/ejhg.2010.129"},{"year":"2007","series-title":"OECD guidelines for quality assurance in molecular genetic testing","author":"Organisation for Economic Co-operation and Development","key":"10.1016\/j.ejca.2018.09.019_bib45"},{"issue":"2","key":"10.1016\/j.ejca.2018.09.019_bib46","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s12687-012-0078-0","article-title":"Genetic testing legislation in Western Europe \u2013 a fluctuating regulatory target","volume":"3","author":"Soini","year":"2012","journal-title":"J Community Genet"},{"issue":"10","key":"10.1016\/j.ejca.2018.09.019_bib47","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/jmedgenet-2017-104531","article-title":"Regulating the advertising of genetic tests in Europe: a balancing act","volume":"54","author":"Kalokairinou","year":"2017","journal-title":"J Med Genet"},{"issue":"12","key":"10.1016\/j.ejca.2018.09.019_bib48","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.2196\/jmir.4378","article-title":"Internet-based direct-to-consumer genetic testing: a systematic review","volume":"17","author":"Covolo","year":"2015","journal-title":"J Med Internet Res"},{"year":"2016","series-title":"Whole genome sequencing in screening for breast cancer","author":"Warren-Gash","key":"10.1016\/j.ejca.2018.09.019_bib49"},{"year":"2014","series-title":"Concordat and moratorium on genetics and insurance","author":"HM Government, Association of British Insurers","key":"10.1016\/j.ejca.2018.09.019_bib50"},{"issue":"4","key":"10.1016\/j.ejca.2018.09.019_bib51","doi-asserted-by":"crossref","first-page":"271","DOI":"10.7326\/M13-2747","article-title":"Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement","volume":"160","author":"Moyer","year":"2014","journal-title":"Ann Intern Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918313893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918313893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T14:25:45Z","timestamp":1544797545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918313893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":51,"alternative-id":["S0959804918313893"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.09.019","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"European Breast Cancer Council manifesto 2018: Genetic\u00a0risk prediction testing in breast cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}